User profiles for Ryan C. Fields
 | Ryan C. Fields, MDProfessor & Chief of Surgical Oncology, Barnes-Jewish Hospital, Alvin J. Siteman … Verified email at wustl.edu Cited by 17651 |
[PDF][PDF] The human tumor atlas network: charting tumor transitions across space and time at single-cell resolution
Crucial transitions in cancer—including tumor initiation, local expansion, metastasis, and
therapeutic resistance—involve complex interactions between cells within the dynamic tumor …
therapeutic resistance—involve complex interactions between cells within the dynamic tumor …
[HTML][HTML] Tumor-on-chip modeling of organ-specific cancer and metastasis
Every year, cancer claims millions of lives around the globe. Unfortunately, model systems
that accurately mimic human oncology – a requirement for the development of more effective …
that accurately mimic human oncology – a requirement for the development of more effective …
Up and down or side to side? A systematic review and meta-analysis examining the impact of incision on outcomes after abdominal surgery
Background The aim of this study was to examine whether midline, paramedian, or transverse
incisions offer potential advantages for abdominal surgery. Data Sources We searched …
incisions offer potential advantages for abdominal surgery. Data Sources We searched …
[PDF][PDF] Tissue-resident macrophages in pancreatic ductal adenocarcinoma originate from embryonic hematopoiesis and promote tumor progression
Tumor-associated macrophages (TAMs) are essential components of the cancer
microenvironment and play critical roles in the regulation of tumor progression. Optimal therapeutic …
microenvironment and play critical roles in the regulation of tumor progression. Optimal therapeutic …
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced …
Background In pancreatic ductal adenocarcinoma, the CCL2–CCR2 chemokine axis is
used to recruit tumour-associated macrophages for construction of an immunosuppressive …
used to recruit tumour-associated macrophages for construction of an immunosuppressive …
NCCN Guidelines® insights: melanoma: cutaneous, version 2.2021: featured updates to the NCCN guidelines
…, D DiMaio, A Durham, RC Fields… - Journal of the National …, 2021 - jnccn.org
Over the past few years, the NCCN Guidelines for Melanoma: Cutaneous have been expanded
to include pathways for treatment of microscopic satellitosis (added in v2. 2020), and the …
to include pathways for treatment of microscopic satellitosis (added in v2. 2020), and the …
[PDF][PDF] Dendritic cell paucity leads to dysfunctional immune surveillance in pancreatic cancer
Here, we utilized spontaneous models of pancreatic and lung cancer to examine how
neoantigenicity shapes tumor immunity and progression. As expected, neoantigen expression …
neoantigenicity shapes tumor immunity and progression. As expected, neoantigen expression …
Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in …
Objective Chemokine pathways are co-opted by pancreatic adenocarcinoma (PDAC) to
facilitate myeloid cell recruitment from the bone marrow to establish an immunosuppressive …
facilitate myeloid cell recruitment from the bone marrow to establish an immunosuppressive …
Cutaneous melanoma, version 2.2019, NCCN clinical practice guidelines in oncology
…, C Contreras, GA Daniels, D DiMaio, RC Fields… - Journal of the National …, 2019 - jnccn.org
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cutaneous
melanoma have been significantly revised over the past few years in response to emerging data …
melanoma have been significantly revised over the past few years in response to emerging data …
[HTML][HTML] Spatially restricted drivers and transitional cell populations cooperate with the microenvironment in untreated and chemo-resistant pancreatic cancer
…, WE Gillanders, F Chen, DG DeNardo, RC Fields… - Nature …, 2022 - nature.com
Pancreatic ductal adenocarcinoma is a lethal disease with limited treatment options and
poor survival. We studied 83 spatial samples from 31 patients (11 treatment-naïve and 20 …
poor survival. We studied 83 spatial samples from 31 patients (11 treatment-naïve and 20 …